Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026

PRESS RELEASE

Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026

Article R. 22-10-23 of the French Commercial Code

Market : Euronext Paris
ISIN code / Mnemo: FR0013233012 / IVA
Web site: www.inventivapharma.com

Notes

1. The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2. The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).
https://www.inventivapharma.com

Contacts

Media Relations

Pascaline Clerc: media@inventivapharma.com
Mark Corbae: inventivapr@icrhealthcare.com

Investor Relations

David Nikodem: IR@inventivapharma.com
Patricia L. Bank: patti.bank@icrhealthcare.com